Therefore, we speculate that ELK4 transcriptionally promotes MSI2 to regulate NSCLC progression through the TGF‐β/SMAD3 pathway, providing a potential novel target for NSCLC treatment. Here, SMAD3 is linked to non-small cell lung carcinoma.